← Back
Data updated: Mar 10, 2026
SHORLA
OncologyImmunology
SHORLA is a pharmaceutical company focused on Oncology, Immunology. Key products include JYLAMVO.
2022
Since
3
Drugs
-
Trials
10
Approved (2yr)
Key Drugs
Recent Activity
TEPYLUTE 2025-12-09
Labeling
NELARABINE 2025-11-06
Labeling
NELARABINE 2025-07-25
Labeling
TEPYLUTE 2025-02-26
Manufacturing (CMC)
JYLAMVO 2024-10-23
Efficacy
JYLAMVO 2024-10-23
Efficacy
NELARABINE 2024-09-13
NELARABINE 2024-09-05
NELARABINE 2024-08-01
TEPYLUTE 2024-06-25
Type 3 - New Dosage Form
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 75%
3 drugs
Immunology 25%
1 drugs
Pipeline Strength Pro
Loading...
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2022-11-29
- Latest
- 2025-12-09
- Applications
- 3